Skip to main content

Verified by Psychology Today

Depression

Treating Depression Using Stanford Neuromodulation Therapy

Is Stanford neuromodulation therapy revolutionizing treatment for depression?

Key points

  • Stanford neuromodulation therapy works by using fcMRI to target a specific area in the frontal lobes.
  • SNT appears to be more effective than many other treatments available.
  • There are reasons to remain somewhat guarded about the effectiveness of SNT.
Sasha Freemind at Unsplash, Creative Commons
Source: Sasha Freemind at Unsplash, Creative Commons

This post was co-authored by Abigail Ramos and Robert T. Muller, Ph.D.

With the development of new neuro-technology and emerging research on the function of the brain, the treatment of mental illness has improved immensely to target symptoms at their source. Transcranial magnetic stimulation (TMS) was developed in 1985 and was considered a breakthrough in treating mental illness. TMS works by targeting brain regions associated with mental illness, such as depression, and sends magnetic pulses to excite underactive neurons, helping to improve one’s mood.

In 2020, the Brain Stimulation Lab at Stanford University modified the TMS protocol to increase its effectiveness in treating major depressive disorder. Stanford neuromodulation therapy (SNT) works by using functional connectivity magnetic resonance imaging (fcMRI) to target a specific area in the frontal lobes. SNT uses intermittent theta-burst stimulation (iTBS), a form of TMS that delivers magnetic pulses at its own distinct frequency. Putting these methods together allows patients to receive more sessions of treatment per day at lower doses, and complete treatment in just a few days rather than weeks. Research has shown remission rates of close to 90%, making SNT appear to be more effective than many other treatments available.

Magnus Medical, a medical device company, has an exclusive license for Stanford Accelerated Intelligence Neuromodulation Therapy (SAINT) technology, a precursor to SNT. Brandon Bentzley, the co-founder of Magnus Medical, explains that SAINT technology is in progress and should be available to the public in 2024. Bentzley also says the global waitlist for SAINT technology is growing rapidly with clinicians and patients interested in the treatment.

Anticipating its release, clinics are beginning to offer SNT treatments without Magnus Medical’s SAINT software. Charles Miller is a nurse anesthesiologist at Scenic City Neurotherapy in Chattanooga, Tennessee, who has been offering ketamine-infused SNT treatment at his clinic for the past year. Miller explains that his clinic follows SNT protocols strictly, with 10 sessions given to the patient for five consecutive days. Ketamine is added to the SNT protocol at the end of days one and five. When comparing ketamine-assisted SNT to other treatments offered in clinic, Miller notes higher remission rates and decreases in depressive symptoms. Miller explains it is important to bear in mind that SNT addresses the physiology of depression but does not treat the psychology behind it. This aspect of depression is addressed with the patient’s mental health provider. If the patient does not have a provider, Miller’s clinic refers them to one in the community: "The goal is not to feel better, but to feel the world correctly."

Source: K. Mitch Hodge/Unsplash, Creative Commons
Source: K. Mitch Hodge/Unsplash, Creative Commons

However, there are reasons to remain somewhat guarded about the effectiveness of SNT.

Khaled Bowarshi from the Florida TMS clinic warns about the negative aspects of SNT that many fail to mention. Bowarshi agrees that SNT represents an enormous advancement in improving the efficacy of TMS treatment. But he mentions that methods used in the SNT protocol were utilized in the past, and this form of treatment is not entirely new.

Bowarshi notes that there is still more research to be done on SNT to demonstrate its effectiveness, highlighting a few critical questions that require investigation. First, is fcMRI the key to SNT’s efficacy, or iTBS? Does the SNT protocol need both methods to be effective, or just one? Also, Bowarshi describes the “fast-on, fast-off” phenomenon, in which remission rates have dropped from approximately 80% to 50% one month after finishing treatment. This raises questions around how durable SNT truly is, and underscores the need to have more studies to investigate the long-term effectiveness of the treatment.

Finally, Bowarshi raises skepticism about whether SNT truly is more effective than classic TMS, saying there is room to question whether these treatments are more similar than previously thought: "If something sounds too good to be true, then it probably is."

The jury may still be out.

To find a therapist, please visit the Psychology Today Therapy Directory.

advertisement
More from Robert T Muller Ph.D.
More from Psychology Today